Atlas Trials

Can Very Low Dose Rivaroxaban in Addition to Dual Antiplatelet Therapy (DAPT) Improve Thrombotic Status in Acute Coronray Syndrome (ACS) ACS

Clinical trial NCT03775746 · UNKNOWN

Trial details

NCT number
NCT03775746
Sponsor
East and North Hertfordshire NHS Trust
Status
UNKNOWN
Phase
Phase 4
Study type
INTERVENTIONAL
Acute Coronary Syndrome
Start date
2019-01-08
Primary completion
2021-12-01
Enrollment
150

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.